Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study

Study (n=123; median duration 1.8 years) found canakinumab provided sustained clinical remission irrespective of fever at treatment initiation (month 6: JADAS or ACR criteria met in 24.3% & 37.1%, respectively of patients with fever and 17.3% & 23.1%, respectively, without fever)

Arthritis & Rheumatology